Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Colgate-Palmolive Company (CL) vs Twist Bioscience Corp (TWST) Price & Performance

Colgate-Palmolive CompanyTrade
Twist Bioscience CorpTrade

Price performance (Past 24H)

Key statistics

Colgate-Palmolive Company vs Twist Bioscience Corp — how do they compare? Colgate-Palmolive Company trades at $92.51 (market cap $73.59B), while Twist Bioscience Corp trades at $122.5 (market cap $7.72B). The key difference: Colgate-Palmolive Company is far larger — about 9.5× Twist Bioscience Corp's market cap, and Colgate-Palmolive Company pays a 2.3% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.

CLTWST
Market Cap
$73.59B$7.72B
Sector
Consumer StaplesHealth
52-Week High
$99.14$124.88
52-Week Low
$74.98$24.16
Enterprise Value
$80.07B$7.65B
Dividend Yield
2.3%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Colgate-Palmolive Company

Colgate-Palmolive (CL) trades at $93.15, down 0.13% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 EPS of $0.99, beating estimates, with 4.9% sales growth driven by emerging markets. However, North American weakness persists, and valuation ratios like P/E of 36.34 and P/B of 311.81 appear elevated. Cash flow remains positive, and a dividend of $0.53 is scheduled for August 2026.

Outlook is mixed: strong brand presence and dividend sustainability support the stock, but high valuation and domestic challenges pose risks. Analyst consensus price target is $99.10, implying modest upside, with 42% buy ratings. Key risks include competitive pressures and margin compression from inflation.

Twist Bioscience Corp

TWST is trading at $124.88, up 7.96% in the last 24 hours, near its pivot point of $121 with resistance at $129. The stock shows strong technical momentum with bullish moving averages, though RSI levels indicate overbought conditions. Revenue growth is robust, with fiscal 2026 Q3 revenue up 23% year-over-year to $118.4 million, but the company remains unprofitable with a net income margin of -31.66% and negative cash flow from operations. Recent news highlights an upsized $300 million public offering and expansion in AI-driven drug discovery.

The outlook for TWST is mixed; bullish analyst sentiment and AI growth potential are offset by persistent losses and high valuation multiples. Investment opportunity lies in sustained revenue expansion and path to profitability, but risks include cash burn, competitive pressures, and execution challenges in scaling operations. The stock's current price exceeds the consensus target of $106.14, suggesting limited near-term upside based on fundamentals.

Returns comparison

Trailing returns across standard periods

About Colgate-Palmolive Company

Since its founding in 1806, Colgate-Palmolive has grown to become a leading global consumer product company. In addition to its namesake oral care line, the firm manufactures shampoos, shower gels, deodorants, and home care products that are sold in over 200 countries (international sales account for about 70% of its consolidated total, including approximately 45% from emerging regions). It also owns specialty pet food maker Hill's, which sells its products through veterinarians and specialty pet retailers.

Read more on CL

About Twist Bioscience Corp

Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.

Read more on TWST